SXC 2023
Alternative Names: SXC-2023Latest Information Update: 02 Jun 2025
At a glance
- Originator Marquette University; University of Wisconsin at Milwaukee
- Developer Promentis Pharmaceuticals
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action SLC7A11 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Impulse control disorders
Most Recent Events
- 30 Dec 2024 National Institute on Drug Abuse in collaboration with Promentis Pharmaceuticals completes a phase I trial for Impulse control disorders in the US (NCT06343532)
- 11 Oct 2024 National Institute on Drug Abuse in collaboration with Promentis Pharmaceuticals initiates a phase I trial for Impulse control disorders in the US (NCT06343532)
- 02 Apr 2024 National Institute on Drug Abuse in collaboration with Promentis Pharmaceuticals plans a phase I trial for Cocaine-related disorders in the US (NCT06343532)